ASCO 2019 | ECOG-E3A06: lenalidomide vs. observation alone in SMM
Sagar Lonial
• 3 Jun 2019
Sagar Lonial, MD, FACP, from the Winship Cancer Institute, Druid Hills, GA, gives us an update on ECOG-E3A06 (NCT01169337), a Phase III randomized trial investigating lenalidomide versus observation alone in asymptomatic high-risk smoldering multiple myeloma (SMM). This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.
